Sector revisions 10x Genomics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
20.81 ^USD	-3.84%		-5.96%	+27.59%

02-20	UBS Adjusts Price Target on 10x Genomics to $20 From $14, Maintains Neutral Rating	MT
02-12	10x Genomics, Inc., Q4 2025 Earnings Call, Feb 12, 2026

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	4m. EPS revision	1y. EPS revision	Visibility	Nbr of analysts
10X GENOMICS, INC.				14
BIOMÉRIEUX				13
GUARDANT HEALTH, INC.				23
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.				10
CARIS LIFE SCIENCES, INC.				10
LANTHEUS HOLDINGS, INC.				13
DIASORIN S.P.A.				12
ANDON HEALTH CO., LTD.	-	-	-	-
AUTOBIO DIAGNOSTICS CO., LTD.				4
VCANBIO CELL & GENE ENGINEERING CORP., LTD			-	-
BEIJING HOTGEN BIOTECH CO., LTD.			-	-
SANSURE BIOTECH INC.				2
VITROLIFE AB				4
GUANGZHOU WONDFO BIOTECH CO.,LTD			-	1
SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD.			-	1
AMOY DIAGNOSTICS CO., LTD.				3
BEIJING STRONG BIOTECHNOLOGIES,INC.			-	-
MACCURA BIOTECHNOLOGY CO.LTD			-	1
Average				8
Weighted average by Cap.				13